FIELD: biotechnology.
SUBSTANCE: group of inventions relates to cell biology. Disclosed are improved methods for reliably depleting TCR+ cells and producing populations of TCR cells, which may be suitable for minimizing the risk of host-versus-graft rejection (HvGD) and graft-versus-host disease (GvHD) in patients receiving allogeneic CAR T- therapy cells. Methods provide for labelling a population of immune cells with an anti-TCR antibody and an anti-CD3 antibody and recovering the immune cells labelled with the anti-TCR antibody, and immune cells labelled with an anti-CD3 antibody from said population of immune cells. Also disclosed is a kit for depletion of cells expressing endogenous TCR, and cell population.
EFFECT: obtained population of immune cells contains at least 99,99% of TCR-cells.
34 cl, 12 dwg, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR PRODUCING ALLOGENIC T-CELLS WITH CAR | 2020 |
|
RU2828787C2 |
| MULTI-CHAIN CHIMERIC ANTIGEN RECEPTOR AND USES THEREOF | 2013 |
|
RU2663725C2 |
| RITUXIMAB-RESISTANT CHIMERIC ANTIGEN RECEPTORS AND WAYS OF USE THEREOF | 2020 |
|
RU2816370C2 |
| COMPOSITIONS AND METHODS FOR BOOSTING THE EFFECTIVENESS OF ADOPTIVE CELL IMMUNOTHERAPY | 2015 |
|
RU2716716C2 |
| EXPRESSION OF NEW CELL MARKS | 2018 |
|
RU2796334C2 |
| CHIMERIC ANTIGENIC RECEPTORS AIMED AT ANTIGEN OF AGING OF B-CELLS | 2016 |
|
RU2706582C2 |
| INSERTION OF TARGET GENE FOR IMPROVED CELLULAR IMMUNOTHERAPY | 2017 |
|
RU2824204C2 |
| GENETICALLY MODIFIED GAMMA DELTA T CELLS | 2015 |
|
RU2756247C2 |
| METHODS OF EXPANSION OF ANTIGEN-SPECIFIC CAR-T-CELLS, COMPOSITIONS AND THEIR USE | 2019 |
|
RU2800920C2 |
| GENETICALLY MODIFIED T CELL RECEPTOR MICE | 2012 |
|
RU2661106C2 |
